Fayez Sarofim & Co
ALXN

Fayez Sarofim & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

Fayez Sarofim & Co’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,075
Closed -$373K – 247
2017
Q1 		$373K Sell
3,075
-9,875
-76% -$1.27M ﹤0.01% 204
2016
Q4 		$1.58M Sell
12,950
-17,806
-58% -$2.18M 0.01% 135
2016
Q3 		$3.77M Sell
30,756
-306,225
-91% -$39.4M 0.02% 117
2016
Q2 		$39.5M Sell
336,981
-9,983
-3% -$1.42M 0.22% 68
2016
Q1 		$48.6M Sell
346,964
-2,199
-0.6% -$323K 0.28% 66
2015
Q4 		$66.1M Buy
349,163
+16,901
+5% +$2.95M 0.38% 65
2015
Q3 		$52.1M Buy
+332,262
New +$60.6M 0.3% 68

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fayez Sarofim & Co's ALXN Position: Q2 2017 in Review

Fayez Sarofim & Co sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 3,075 shares — an estimated $373K sold.

Fayez Sarofim & Co first reported a position in ALXN in Q3 2015 and held it in 7 quarters. The position peaked at $66.1M in Q4 2015. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

  • Fayez Sarofim & Co reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Fayez Sarofim & Co sold 3,075 Alexion Pharmaceuticals shares in Q2 2017, an estimated $373K.
  • Fayez Sarofim & Co first reported a position in Alexion Pharmaceuticals in Q3 2015 and held it in 7 quarters.
  • Fayez Sarofim & Co's Alexion Pharmaceuticals position peaked at $66.1M in Q4 2015.
  • 559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Fayez Sarofim & Co's 13F filing for Q2 2017, filed 11 Aug 2017.